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Abstract: By using a semi-quantitative immunoblotting technique, we have analyzed serum 
immunoglobulin G (IgG) reactivities of patients with limited cutaneous systemic sclerosis 
and anticentromere antibodies, patients with diffuse systemic sclerosis and antitopoisomerase 
1 antibodies, patients with diffuse systemic sclerosis without antitopoisomerase 1 or anticen-
tromere antibodies and age- and gender-matched healthy controls with normal human skin 
ﬁ  broblasts and HEp-2 cells antigens. Serum IgG reactivities of patients with diffuse systemic 
sclerosis and antitopoisomerase 1 antibodies differed signiﬁ  cantly from those of healthy con-
trols or systemic sclerosis patients in other groups for reactivity with ﬁ  broblast proteins. IgG 
from patients with antitopoisomerase 1 antibodies bound to a 90 kDa ﬁ  broblast band and to a 
100 kDa protein band in a HEp-2 cell protein extract. These two bands were further identiﬁ  ed 
as DNA topoisomerase 1. Our results indicate that IgG from patients with diffuse systemic 
sclerosis bind DNA topoisomerase 1 in normal human ﬁ  broblasts extracts.
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Introduction
Systemic sclerosis (SSc) is a connective tissue disease characterized by vascular 
hyperreactivity, obliterative microvascular phenomena and by skin and internal organs 
ﬁ  brosis. Endothelial cells, ﬁ  broblasts and leukocytes, particularly monocytes and 
lymphocytes participate in the pathogenesis of the disease, although none of these 
cells has been identiﬁ  ed as the unique initiating factor (Tamby et al 2003; Servettaz 
et al 2006).
Several lines of evidence suggest that unchecked activation of ﬁ  broblasts is involved 
in SSc. Thus, ﬁ  broblasts from SSc patients are activated to produce high amounts 
of extracellular matrix proteins such as types I and III collagens, proteoglycans, 
ﬁ  bronectin, and metalloproteinase inhibitors (Leask et al 2002). This might result 
from constitutive dysregulations of transforming growth factor beta (TGFβ) signal-
ing pathway or from the inﬂ  uence of environmental factors, ie, excess of cytokines 
synthesis or targeting by autoantibodies.
Many autoantibodies have been detected in the serum of SSc patients, including 
disease speciﬁ  c such as anticentromere antibodies, associated with limited cutaneous 
SSc (Moroi et al 1980; Steen et al 1988); antitopoisomerase 1 antibodies associated 
with diffuse SSc (Steen et al 1988; Weiner et al 1988); and anti-RNA-polymerase 
III antibodies which are associated with renal involvement (Bunn et al 1998). In 
addition, non speciﬁ  c autoantibodies have also been identiﬁ  ed in the serum of SSc 
patients, including antiﬁ  brillin 1 (Tan et al 1999), antiendothelial cell antibodies 
(AECA) (Ihn et al 2000; Sgonc et al 2000; Garcia de la Pena-Lefebvre et al 2004), 
and antiﬁ  broblast antibodies (AFA) (Brentnall et al 1982; Alderuccio et al 1989; Biologics: Targets & Therapy 2008:2(3) 584
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Chizzolini et al 2002; Ronda et al 2002; Zhou et al 2005; 
Baroni et al 2006). Antiﬁ  broblast antibodies can activate 
ﬁ  broblasts and induce extracellular matrix proteins synthesis 
(Chizzolini et al 2002). DNA topoisomerase 1 was recently 
identiﬁ  ed as a target of AFA (Henault et al 2004). However, 
further experiments provided evidence that these antibodies 
did not target directly topoisomerase 1 expressed at the 
ﬁ  broblast surface but rather recognized membrane-bound 
topoisomerase 1 (Henault et al 2004). Other target antigens 
of antiﬁ  broblast antibodies have been identiﬁ  ed: namely 
ﬁ  brillin-1 (Zhou et al 2005) and platelet-derived growth 
factor (PDGF) receptor (Baroni et al 2006).
In order to conﬁ  rm these results and/or to identify speciﬁ  c 
target antigens of AFA in SSc patients, we decided to analyze 
reactivity patterns of immunoglobulin G (IgG) and IgM from 
SSc patients and age- gender-, and parity-matched healthy 
controls with ﬁ  broblasts.
Materials and methods
Patients
All patients gave their written informed consent. Limited 
cutaneous SSc was deﬁ  ned by skin thickening in areas 
solely distal to the elbows and knees, with or without facial 
involvement; diffuse SSc was deﬁ  ned by the presence of 
skin thickening proximal, as well as distal, to the elbows 
and knees, with or without facial or truncal involvement 
(LeRoy et al 1988). Sixty patients were included in the 
study: 20 (16 females and 4 males, mean age 53.5 ± 15.2 
years) with diffuse SSc and antitopoisomerase 1 antibodies, 
20 (all females, 56.7 ± 12.8 years) with limited cutaneous 
SSc and anticentromere antibodies and 20 (14 females and 
6 males, mean age 50.9 ± 10.9 years) with diffuse SSc and 
no antitopoisomerase 1 or anticentromere antibody. For these 
3 groups, disease durations were measured from the onset 
of ﬁ  rst non-Raynaud’s phenomenon symptom (11.3 ± 9.6 
years, 9.4 ± 9.5 years, 5.6 ± 5.4 years in the 3 groups, 
respectively). Interstitial lung disease, assessed by chest 
high-resolution computed tomodensitometry and abnormal 
pulmonary function test values (total lung capacity or vital 
capacity less than 80% of predicted values and/or diffusing 
capacity 75% of that predicted) was present in all patients 
with antitopoisomerase 1 antibodies, in 13 patients without 
antitopoisomerase 1 or anticentromere antibody and none 
of the patients with anticentromere antibodies. Pulmonary 
arterial hypertension, deﬁ  ned as systolic pulmonary artery 
pressure was 40 mm Hg (Mukerjee et al 2003) as mea-
sured by Doppler echocardiography, was diagnosed in 
4 patients with antitopoisomerase 1 antibodies, 2 patients 
with anticentromere antibodies and 3 patients without 
antitopoisomerase 1 or anticentromere antibody. None of 
the patients included had cancer or another connective tis-
sue disease. None of the patients received corticosteroids or 
immunosuppressive therapy. Sixty unrelated healthy age-, 
gender- and parity-matched donors served as controls.
Ig sources
Serum samples were obtained from patients and controls and 
stored in aliquots at –80 °C until tested. Mean serum IgG 
and IgM concentrations determined by nephelometry were 
respectively: 10.6 ± 2.9 and 1.4 ± 0.8 mg/ml in patients with 
anticentromere antibodies, 13.9 ± 3.9, 1.7 ± 0.74 mg/ml in 
patients with antitopoisomerase 1 antibodies, 14.4 ± 3.3 and 
1.9 ± 1.0 mg/ml in patients without speciﬁ  c autoantibody 
and 12.0 ± 2.8 and 1.6 ± 0.7 in healthy controls. Serum IgG 
and IgM concentrations did not differ signiﬁ  cantly between 
patients in the different groups and controls. A therapeutic 
preparation of normal human IgG, intravenous immuno-
globulin (IVIg) and normal human polyclonal IgM (LFB, 
Les Ulis, France) served as internal standards.
Cell culture
Fibroblasts
Normal human dermal ﬁ  broblasts were cultured from his-
tologically normal skin obtained in 3 donors undergoing 
resection of basocellular carcinoma. Biopsy specimen were 
cut into small sections and seeded into Petri dishes and 
then into 162 cm2 plastic ﬂ  asks. Fibroblasts were grown in 
Dulbecco’s modiﬁ  ed Eagle’s medium (DMEM) with 10% 
heat-inactivated fetal calf serum, 2 mM L-glutamine, 10 mM 
Hepes, 100 U/ml penicillin, 100 μg/ml streptomycin (Life 
Technologies Ltd, Auckland, NZ) at 37 °C in 5% CO2. When 
conﬂ  uent, the cells were detached using 0.05% trypsin with 
2 μM EDTA.
HEp-2 cells
HEp-2 cells were obtained from EuroBio (Les Ulis, France) 
and cultured at 37 °C in 5% CO2 in 162 cm2 ﬂ  asks in DMEM 
supplemented with 10% heat-inactivated fetal calf serum, 
2 mM L-glutamine, 10 mM hepes, 20 mM sodium pyruvate, 
100 U/ml penicillin, 100 μg/ml streptomycin (Life Technolo-
gies Ltd). When conﬂ  uent, the cells were detached using 
0.05% trypsin, 2 μM EDTA.
Detection of antibody reactivities
For each patient and healthy control, antinuclear antibod-
ies were investigated by indirect immunoﬂ  uorescence on Biologics: Targets & Therapy 2008:2(3) 585
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HEp-2 cells and considered positive at a dilution 1/160. 
Anticentromere antibodies were characterized by a pattern 
of discrete dots in cells lined up on the metaphase plate in 
dividing interphase cells. Antitopoisomerase 1 antibodies 
were detected by ELISA with a commercial kit (Inova Diag-
nostics Inc, San Diego, CA, USA) using puriﬁ  ed calf thymus 
topoisomerase 1 and sera diluted 1:100.
IgG and IgM reactivities were analyzed using a semi-
quantitative immunoblotting technique with normal human 
dermal fibroblasts and HEp-2 cells. Cellular protein 
extracts were performed in a buffer containing 4% sodium 
dodecyl sulfate, 1.45 M 2-mercaptoethanol, 125 mM 
Tris/HCl pH 6.8, 1 μg/ml aprotinin, 1 μg/ml pepstatin and 
1 μg/ml leupeptin and then sonicated 4 × 30 s (Chanseaud 
et al 2003; Garcia de la Pena-Lefebvre et al 2004). Equal 
amounts of solubilized proteins were subjected to prepara-
tive sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis through 10% polyacrylamide gels. The proteins 
were then transferred onto nitrocellulose membranes for 
1 h at 0.8 mA/cm2 using a semi-dry electroblotter model 
A (Ancos, Hojby, Denmark). After blocking with phosphate 
buffer saline –0.2% Tween® for 90 min, the membranes 
were incubated with sera for 4 h at room temperature at 
200 μg/mL for IgG and 20 μg/mL for IgM in a cassette 
miniblot system (Immunetics Inc., Cambridge, MA, USA). 
They were then extensively washed before being incubated 
with secondary rabbit antihuman Fc-γ of antihuman Fc-μ 
antibody coupled to alkaline phosphatase (Dakocytomation, 
Golstrup, Denmark) for 90 min at room temperature. Immu-
noreactivities were revealed using the nitroblue tetrazolium-
5-bromo-4-chloro-3-indolyl-phosphate substrate (Sigma, 
St. Louis, MO, USA) (Garcia de la Pena-Lefebvre et al 
2004; Tamby et al 2005). Immunoreactivities were quanti-
ﬁ  ed by scanning the membranes with a densitometer (Epson 
Perfection 1200S, Seiko Epson Corporation, Nagano-Ken, 
Japan). The membranes were then stained with colloidal 
gold (Protogold;® Biocell, Cardiff, UK) and subjected to 
a second densitometric analysis to quantify transferred 
proteins. This approach allows the immunoreactivity rep-
ertoires to be compared by referring to their respective pro-
tein peaks corrected for electrophoretic migration defects 
by superimposing corresponding protein peaks by means 
of computer analysis. Standard IgM or IgG preparations 
included in each blot, allow the rescaling of the membranes 
transferred with a given protein extract and to adjust for the 
intensity of labelling on different membranes (Chanseaud 
et al 2003; Garcia de la Pena-Lefebvre et al 2004). All 
experiments were performed twice.
Rabbit polyclonal antibody raised against amino acids 
685–765 of human DNA topoisomerase 1 recombinant pro-
tein (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was 
tested in immunoblots during 90 min at room temperature 
at dilutions of 1:500, and 1:1000 for reactivity with ﬁ  bro-
blasts proteins extracts. Immunoreactivities were assayed 
using an alkaline phosphatase conjugated goat antirabbit 
IgG antibody (Santa Cruz) and revealed using nitroblue 
tetrazolium-5-bromo-4-chloro-3-indolyl-phosphate) (Sigma).
Protein sequencing
To identify the target antigens, we performed an additional 
SDS-PAGE protein electrophoresis with a ﬁ  broblast extract 
in 10% polyacrylamide gels and dissected bands of interest. 
We then performed a passive adsorption onto a polyvinyle 
diﬂ  uoride (PVDF) membrane (Messer et al 1997) and not 
an electrotransfer, in order to favor the protein binding onto 
the membrane in a nondestructive manner for subsequent 
analysis of the separated proteins of interest. The proteins 
were derivatized and sequenced by automated Edman’s 
degradation using a PE Applied Biosystems 492 cLC protein 
sequencer (Perkin Elmer, Wellesley, MA, USA) allowing the 
identiﬁ  cation and quantiﬁ  cation in the range of femtomoles 
of the amino acids released.
Statistical analyses
Because of the large number of reactivities identiﬁ  ed in the 
blots, we decided to submit the data to multivariate statistical 
analysis. Therefore we used IGOR software (Igor Pro 3.16, 
Wavemetrics Inc, Lake Oswego, OR, USA) with specially 
designed software packages (Nobrega et al 1993), and Stat-
view software (Statview 5.0; SAS institute Inc., Cary, NC, 
USA). Densitometry curves of IgG and IgM reactivities 
of each patient and control on each of the different protein 
extracts were divided into sections surrounding individual 
peaks of immunoreactivity on each substrate. In order to 
discriminate between groups of individuals, the peak ampli-
tudes corresponding to these sections were submitted to 
principal component analysis (Nobrega et al 1993; Mouthon 
et al 1996). Principal component analysis data were then 
subjected to linear discriminant analysis, and the individual 
linear discriminant analysis factor 1 coordinates of each 
patient or healthy control in the 2 groups were compared 
using a paired Wilcoxon test. Repertoires of reactivities of 
patients in each group were compared two by two by using the 
same procedure, except that the individual linear discriminant 
analysis factor 1 coordinates of each patient in the 2 groups 
were compared using a Mann-Whitney test.Biologics: Targets & Therapy 2008:2(3) 586
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Results
IgG and IgM reactivities of patients 
and healthy controls with ﬁ  broblast 
antigens
IgG and IgM reactivity patterns with ﬁ  broblast antigens 
were homogeneous in terms of protein bands recognized 
and intensity of reactivities among healthy individuals and 
patients in each group. As depicted in Figure 1, IgG from 
healthy individuals bound to 5 to 8 protein bands in the 
ﬁ  broblast extract, with expression of three main immuno-
reactivities of approximately 53, 44, and 33 kDa, respec-
tively (Figure 1A). Two other minor IgG reactivities were 
directed against low molecular weight proteins, and some 
patients expressed individual speciﬁ  c reactivities. IgG from 
patients in the different groups also bound to 6 to 10 protein 
bands in the ﬁ  broblast extract including immunoreactivities 
directed toward the same 53, 44, and 33 kDa bands. In addi-
tion to these bands, IgG from patients with limited cutaneous 
SSc and anticentromere antibodies (Figure 1B) bound with 
low intensity to a 80 kDa antigen. IgG from patients with 
diffuse SSc and antitopoisomerase 1 antibodies (Figure 1C) 
expressed a high intensity reactivity with the 44 kDa protein 
band as compared with those expressed by IgG from patients 
in other groups and healthy controls. Interestingly, almost all 
patients with diffuse SSc and antitopoisomerase 1 antibodies 
bound to two 90 and 65 kDa protein bands, whereas IgG 
from patients with limited cutaneous SSc and anti anticen-
tromere antibodies and healthy controls did not. Finally, IgG 
from several patients without speciﬁ  c autoantibody bound to 
the two 90 and/or 65 kDa ﬁ  broblasts protein bands, whereas 
other patients in this group did not (Figure 1D). IgG from 
several patients in each group expressed individual speciﬁ  c 
reactivities.
IgM from patients and healthy individuals bound to three to 
ﬁ  ve protein bands in the ﬁ  broblast extract and with a high inten-
sity reactivity with the 53kDa protein band (data not shown).
Multiparametric analysis of IgG and 
IgM reactivities of patients and healthy 
controls with ﬁ  broblast antigens
IgG and IgM reactivities from patients in each group and 
healthy controls were compared by performing principal 
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Figure 1 Densitometric proﬁ  les of immunoglobulin G (IgG) reactivity of 10 healthy controls (A), 10 patients with limited cutaneous systemic sclerosis (SSc) and anticentromere 
antibodies (B), 10 patients with diffuse SSc and antitopoisomerase 1 antibodies (C), 10 patients with diffuse SSc without antitopoisomerase 1 or anticentromere antibody 
(D) with ﬁ  broblasts antigens. Sera were diluted to an IgG concentration of 200 μg/ml. The densitometric pattern of IgG reactivities of each individual is depicted as a full line 
curve. Hatched areas depict the densitometric pattern observed in the presence of the secondary anti-Fcγ antibody tested alone. Molecular weights are expressed as kDa in 
the abscissa, and optical densities are expressed as arbitrary units (A.U.) in the ordinates.Biologics: Targets & Therapy 2008:2(3) 587
Antiﬁ  broblasts antibodies in systemic sclerosis
component analysis followed by linear discriminant analysis 
and non parametric tests, as previously described. IgG reac-
tivities from patients with diffuse SSc and antitopoisomerase 
1 antibodies with ﬁ  broblasts antigens different signiﬁ  cantly 
from those of healthy controls, whereas no signiﬁ  cant dif-
ference was observed between limited cutaneous SSc with 
anticentromere antibodies and their controls and diffuse SSc 
without antitopoisomerase 1 or anticentromere antibody and 
their controls (Table 1).
IgM reactivities from patients with limited cutaneous SSc 
with anticentromere antibodies were signiﬁ  cantly different 
from those of healthy controls, whereas no signiﬁ  cant dif-
ference was observed between patients in other groups and 
their respective healthy controls (Table 1).
Multiparametric analysis of serum reactivities from 
patients compared two by two differed in the case of IgG from 
patients with diffuse SSc with antitopoisomerase 1 antibod-
ies vs patients with diffuse SSc without antitopoisomerase 
1 or anticentromere antibody and in the case of IgM from 
patients with diffuse SSc and antitopoisomerase 1 antibodies 
vs patients with limited cutaneous SSc with anticentromere 
antibodies (Table 2).
IgG and IgM reactivities of patients 
and healthy controls with HEp-2 cells 
antigens
In order to better characterize the cell speciﬁ  city of AFA, 
we further performed experiments with HEp-2 cells, the 
reference source of nuclear antigens. IgG reactivity patterns 
were relatively homogeneous among healthy individuals and 
among patients in each group when tested toward HEp-2 cells 
protein extracts. IgG from patients with antitopoisomerase 
1 antibodies recognized 3–6 protein bands in HEp-2 cells 
extract, including one major band of 100-kDa, whereas IgG 
from patients with anticentromere antibodies recognized 4–8 
bands, including two major bands of 65 and 80 kDa, whereas 
none of them bound to the 100-kDa band (Figure 2). IgG 
from patients without antitopoisomerase 1 or anticentromere 
antibody recognized 6–10 HEp-2 cells bands, including the 
100-kDa protein band in 5/20. IgM reactivity patterns with 
HEp-2 cells protein extracts were relatively homogeneous 
among healthy individuals and among patients in each 
group. No difference was observed between IgM reactivi-
ties of patients in each group and healthy individuals (data 
not shown).
Multiparametric analysis of IgG and IgM 
reactivities of patients and healthy controls 
with HEp-2 cells antigens
Principal component analysis of the data discriminated 
between the IgG reactivity patterns of SSc patients in each 
group and healthy controls as well as between patients in 
the different groups compared two by two (Tables 1 and 2). 
IgM reactivity patterns with HEp-2 cells protein extracts 
were relatively homogeneous among healthy individuals 
and among patients in each group. No signiﬁ  cant differ-
ence was observed between IgM reactivities of patients 
in each group and controls or between patients in each 
group tested two by two, with the exception of patients 
with antitopoisomerase 1 antibodies versus healthy indi-
viduals (Tables 1 and 2). We thus demonstrated that IgG 
reactivities from SSc patients in the different groups were 
not speciﬁ  c to ﬁ  broblasts antigens but also bound HEp-2 
cells antigens.
Characterization of the 100-kDa target 
antigen in ﬁ  broblasts
We incubated the ﬁ  broblast protein extract with rabbit 
polyclonal antibodies raised against amino acids 685–765 
of human DNA topoisomerase 1 recombinant protein as 
indicated in Materials and methods. This antibody bound 
to the same 90 kDa protein band that was recognized by 
serum IgG from patients with antitopoisomerase 1 antibodies 
(data not shown). We also tested the polyclonal goat anti-
topoisomerase 1 antibody on HEp-2 protein extract and 
Table 1 Multiparametric analysis of serum immunoglobulin G (IgG) 
and IgM reactivities from patients with diffuse systemic sclerosis 
(SSc) with antitopoisomerase 1 antibodies, patients with limited 
cutaneous SSc with anticentromere antibodies and patients with dif-
fuse SSc without antitopoisomerase 1 or anticentromere antibody 
compared to their respective healthy controls on normal human 
ﬁ  broblasts and HEp-2 cells antigens
Patients Fibroblasts HEp-2
IgG IgM IgG IgM
Diffuse SSc with 
antitopoisomerase 
1 antibodies
0.03* 0.29 0.01* 0.01*
Limited cutaneous 
SSc with anticen-
tromere antibodies
0.17 0.01* 0.02* 0.28
Diffuse SSc without 
antitopoisomerase 
1 or anticentro-
mere antibodiy
0.55 0.37 0.02* 0.21
Note: * signiﬁ  cant differenceBiologics: Targets & Therapy 2008:2(3) 588
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observed that this Ab bound to the 100 kDa protein band 
(data not shown).
We further sequenced the 90-kDa protein band, as 
described in Materials and methods. DNA-topoisomerase 
I was identiﬁ  ed by sequencing the 10 to 25 N-terminal 
amino acids: SQIEADFRLNDSHKH of this protein. 
Thus, the N-terminal sequence of the protein started at 
position 10, suggesting a lysis of the nine ﬁ  rst amino 
acids during preparation of the protein sample (data not 
shown). Thus, AFA from patients with diffuse SSc with or 
Table 2 Multiparametric analysis of serum immunoglobulin G (IgG) and IgM reactivities from patients with diffuse systemic sclerosis 
(SSc) with antitopoisomerase 1 antibodies, patients with limited cutaneous SSc with anticentromere antibodies and patients with dif-
fuse SSc without antitopoisomerase 1 or anticentromere antibody compared two by two on normal human ﬁ  broblasts and HEp-2 cells 
antigens
Patients Fibroblasts HEp-2
IgG IgM IgG IgM
diffuse SSc with antitopoisomerase 1 
antibodies vs. limited cutaneous SSc 
with anticentromere antibodies
0.11 0.01* 0.0001* 0.14
diffuse SSc with antitopoisomerase 1 
antibodies vs. diffuse SSc without anti-
topoisomerase 1 or anticentromere 
antibody
0.02* 0.051 0.0001* 0.07
limited cutaneous SSc with anticen-
tromere antibodies vs. diffuse SSc 
without antitopoisomerase 1 or 
anticentromere antibody
0.4 0.72 0.01* 0.76
Note: * signiﬁ  cant difference
B A
100
80
60
40
20
0
20 35 55 100 200 30 65
100
80
60
40
20
0
20 35 55 100 200 30 65
O
p
t
i
c
a
l
 
d
e
n
s
i
t
y
 
(
A
.
U
.
)
D C
100
80
60
40
20
0
20 35 55 100 200 30 65
Molecular weight (kDa)
100
80
60
40
20
0
20 35 55 100 200 30 65
Figure 2 Densitometric proﬁ  les of immunoglobulin G (IgG) reactivity of 10 healthy controls (A), 10 patients with limited cutaneous systemic sclerosis (SSc) and anticentromere 
antibodies (B), 10 patients with diffuse SSc and antitopoisomerase 1 antibodies (C), 10 patients with diffuse SSc without antitopoisomerase 1 or anticentromere antibody 
(D) with ﬁ  broblasts antigens. Sera were diluted to an IgG concentration of 200 μg/ml. The densitometric pattern of IgG reactivities of each individual is depicted as a full line 
curve. Hatched areas depict the densitometric pattern observed in the presence of the secondary anti-Fcγ antibody tested alone. Molecular weights are expressed as kDa in 
the abscissa, and optical densities are expressed as arbitrary units (A.U.) in the ordinates.Biologics: Targets & Therapy 2008:2(3) 589
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without antitopoisomerase 1 antibodies bind to ﬁ  broblast 
topoisomerase 1.
Discussion
It is now well established that SSc patients express antiﬁ  -
broblasts antibodies (Brentnall et al 1982; Alderuccio et al 
1989; Chizzolini et al 2002; Ronda et al 2002; Henault et al 
2004). Chizzolini and colleagues (2002) reported that the 
prevalence of AFA was signiﬁ  cantly higher in diffuse SSc 
than in limited cutaneous SSc patients. Thus, our observation 
that limited cutaneous or diffuse SSc exhibit signiﬁ  cantly 
different reactivity patterns with ﬁ  broblasts antigens is not 
unexpected. Unfortunately, in their report, Chizzolini and 
colleagues do not mention the prevalence of antitopoisom-
erase 1 antibodies in SSc patients tested.
To our knowledge, very few studies investigated the spec-
iﬁ  city of AFA in SSc patients. We here provide evidence that 
IgG from diffuse SSc patients with antitopoisomerase 1 anti-
bodies express two main bands of reactivity of 65 and 90 kDa 
with ﬁ  broblasts antigens, whereas patients with limited cuta-
neous SSc and anticentromere antibodies and healthy controls 
do not. Our patients had IgG antitopoisomerase 1 antibodies, 
and we knew from the literature that antitopoisomerase 1 IgG 
reactivities may bind to a 70 kDa protein band corresponding 
to a degraded form of topoisomerase 1 in cellular extracts. 
Thus, we postulated that IgG immunoreactivities identiﬁ  ed 
in these patients might be directed to topoisomerase. This 
was conﬁ  rmed by N-terminal sequencing, since an amino 
acid sequence compatible with N-terminal sequence of 
DNA topoisomerase 1 was identiﬁ  ed in the 90 kDa band. 
Although we did not perform any experiment to identify 
the same target antigen in the 65 kDa band, we postulate 
that this band also contains DNA topoisomerase 1. Thus, it 
has now been well documented for near twenty years that 
patients with SSc bind to a 70 kDa antigen in Hela cells 
extracts and that the target antigen of the anti-Scl-70 Abs 
is a degraded form of topoisomerase 1 (Kumar et al 1988), 
and it was postulated that reactivities directed towards Hela 
cells proteins of 63 to 77 kDa molecular weights bound to 
topoisomerase 1 (Briolay et al 1989).
Importantly, our data conﬁ  rm the ﬁ  nding of Henault 
and colleagues (2004) who recently identified DNA 
topoisomerase 1 as the target of AFA, with evidence that 
antitopoisomerase 1 antibodies display antiﬁ  broblast activity 
by reacting with determinants at the ﬁ  broblast surface.
Although it has not been demonstrated yet, one may 
speculate that IgG antitopoisomerase 1 antibodies from 
patients with diffuse SSc might bind to their target antigen 
at the ﬁ  broblast surface and activate these cells. Indeed, in 
SSc patients, AFA have been shown to induce ﬁ  broblasts 
activation in vitro and a pro-adhesive and pro-inﬂ  ammatory 
phenotype of these cells (Chizzolini et al 2002). Thus, IgG 
binding to the surface of ﬁ  broblasts could induce an autocrine 
production of cytokines such as interleukin (IL)-1α, IL-1β, 
and IL-6 which could up-regulate the adhesive molecule 
intercellular adhesion molecule-1 on fibroblast surface 
(Chizzolini et al 2002).
Interestingly, we have previously analyzed IgG antibodies 
repertoires in SSc patients and shown that IgG reactivity with 
a 100-kDa tissue and endothelial cell antigen identiﬁ  ed as 
topoisomerase 1 distinguished between limited cutaneous 
and diffuse SSc patients (Garcia de la Pena-Lefebvre et al 
2004), whereas two 75- and 85-KDa protein bands identiﬁ  ed 
as centromeric protein B were recognized by patients with 
limited cutaneous SSc (Servettaz et al 2006).
Prominent recognition of a 90 kDa band in ﬁ  broblasts 
versus a 100 kDa band in endothelial cells (Garcia de la 
Pena-Lefebvre et al 2004) or HEp-2 cells might be the con-
sequence of discrepancies in the amounts of proteases or 
free radicals in the different cell culture mediums between 
ﬁ  broblasts, HEp-2 cells, and endothelial cells.
In the present report, IgG from close to 50% of patients 
without antitopoisomerase 1 or anticentromere antibody 
bound to two 65 and/or 100 kDa ﬁ  broblasts protein bands, 
with prominent binding to the 65 kDa Hep-2 cell protein 
band. These data conﬁ  rm those obtained in previous work 
performed with endothelial cell antigens that IgG from 50% 
of patients without antitopoisomerase 1 or anticentromere 
antibody, as assessed by ELISA, bound to the 100-kDa 
endothelial cell antigen identiﬁ  ed as topoisomerase 1 
(Garcia de la Pena-Lefebvre et al 2004). Thus, IgG from 
SSc patients with antinuclear antibodies without docu-
mented antitopoisomerase 1 speciﬁ  city as assessed ELISA 
may bind to 90 kDa protein bands in ﬁ  broblasts extracts 
and/or 100 kDa antigens in endothelial cells and HEp-2 
cell extracts. Thus, in previous work, we reported that 
antitopoisomerase 1 antibodies were detected in 9 (8.1%) 
patients who had no antitopoisomerase 1 antibody as 
determined by ELISA. Patients with antitopoisomerase 
1 antibodies had an almost similar phenotype without 
distinction between ELISA or immunoblot approaches 
(Tamby et al 2007).
Reactivities detected by immunoblotting reﬂ  ect the 
speciﬁ  c binding of the variable regions of IgM and IgG 
antibodies to tissue antigens (Mouthon et al 1995). Since 
we used the same ﬁ  broblasts sources to test all patients, Biologics: Targets & Therapy 2008:2(3) 590
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it could be argued that some of the scored reactivities 
could be speciﬁ  c to alloantigens. Moreover graft versus 
host disease reactions attributable to the persistence of 
allogeneic fetal cells in the skin of women for years after 
the pregnancy have been proposed to play a role in the 
development of SSc (Artlett et al 1998; Nelson et al 1998). 
In this study, female SSc patients were matched with 
healthy women for parity, and in light of the absence of 
any difference between them, it is extremely unlikely that 
alloantigen recognition could explain the results obtained 
herein. Finally, the approach does not exclude that some of 
the epitopes identiﬁ  ed by IgG in immunoblots may differ 
from those expressed by native proteins. The technique 
allows, however, for the comparative analysis of reper-
toires of Igs from different individuals (Artlett et al 1998; 
Nelson et al 1998).
We here provide evidence that IgG from patients with 
limited cutaneous or diffuse SSc exhibit signiﬁ  cantly differ-
ent reactivity patterns with ﬁ  broblasts antigens, and conﬁ  rm 
that IgG from patients with diffuse SSc bind to topoisomerase 
1 in ﬁ  broblasts extracts. The function of these antibodies 
needs to be investigated.
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